(McGill University Health Centre) — The Research Institute of the McGill University Health Centre (RI-MUHC) will host a new Phase 3 randomized clinical trial called TROPION-Breast04, as announced today by the McPeak-Sirois Group, a provincial consortium of cancer centres across Quebec focused on breast cancer research.
This trial is intended for patients with triple-negative breast cancer (TNBC) or hormone-receptor (HR)-low/HER2-negative early stage breast cancer who have not yet received treatment. The trial will evaluate the safety and efficacy of neoadjuvant datopotamab deruxtecan (or Dato-DXd) in combination with durvalumab, followed by adjuvant durvalumab with or without chemotherapy compared to existing standard treatment for TNBC. We are proud to report that the first patient worldwide to be enrolled in this pivotal trial is a patient of the Cedars Cancer Centre of the McGill University Health Centre (MUHC).
TNBC has a high recurrence rate and a high potential for metastasis. It shows resistance to conventional treatments, leading to poor prognosis and survival outcomes. TNBC tends to be more common in women under 40 years of age. There is a need for novel and more effective treatment approaches, hence the excitement for the TROPION-Breast04 clinical trial which has the potential to improve the lives of eligible patients in this setting. (…)